BioCentury
ARTICLE | Company News

Cell Cure Neurosciences, Teva deal

October 25, 2010 7:00 AM UTC

Cell Cure, a majority-owned subsidiary of BioTime Inc. (NYSE-A:BTX), granted Teva an exclusive option to license exclusive, worldwide rights to develop and commercialize Cell Cure's OpRegen to treat...